CD274 and hepatocellular carcinoma: Amongst these, the combination of atezolizumab, an anti-PD-L1 antibody, and bevacizumab, an anti-VEGF antibody approved as the first-line therapy for advanced HCC, has prolonged HCC patient survival at least 2-fold compared to sorafenib.